Abstract. Animal models of Alzheimer's disease (AD) have been extensively utilized for decades in an effort to elucidate the pathophysiological mechanisms of this disease and to test novel therapeutic approaches. However, research success has not effectively translated into therapeutic success for human patients. This translational failure is partially due to the overuse of animal models that cannot accurately recapitulate human AD etiopathogenesis or drug responses and the inadequate use of human-relevant research methods. Here, we propose how to mitigate this translational barrier by employing human-based methods to elucidate disease processes occurring at multiple levels of complexity, accounting for gene and protein expression and the impact of disease at the cellular, tissue/organ, individual, and population levels. In particular, novel human-based cellular and computational models, together with epidemiological and clinical studies, represent the ideal tools to facilitate human-relevant data acquisition, in the effort to better elucidate AD pathogenesis in a human-based setting and design more effective treatments and preventive strategies. Our analysis indicates that a paradigm shift toward human-based, rather than animal-based research is required in the face of the ever-increasing prevalence of AD in the 21st century.
INTRODUCTION
Alzheimer's disease (AD) represents the most common cause of dementia, accounting for 50-75% of all dementia cases [1] . This is a devastating disease affecting every aspect of life, as AD patients progress from very mild to severe cognitive impairment, losing their memory, their relationships with their families, and their ability to perform daily functions, such as talking, eating, and walking. The number of people living with AD in the United States alone is expected to increase from 5.2 million in 2013 to 13.8 million in 2050 [2] , with an estimated cost of care expected to reach more than $1 trillion per year [1, 3] . It is clear that effective preventive and therapeutic strategies are urgently needed. In this regard, the AD research community has been very active with extensive research efforts designed to elucidate disease mechanisms and to develop novel therapeutics. However, these efforts have not successfully translated into effective drugs for AD patients. To date, only three drugs have been approved for AD (donepezil, galantamine, and rivastigmine) and they can only treat the symptoms of AD. It is well known that they are effective in only a small subset of patients, and only for a limited period of time [4] . Since 1998, 101 potential AD drugs have advanced to human trials but failed [5] , and with recent costly failures such as Dimebon [6] , drug companies are downgrading their efforts to develop novel pharmacotherapeutics for AD [7] . Understanding and resolving the reasons for these translational failures in AD is therefore imperative. Additionally, several lines of evidence indicate that AD should be reinterpreted as part of a constellation of diseases, in particular, as a complex systemic/metabolic dysfunction, given the significant correlations found between AD and the metabolic syndrome [8] , as well as hypometabolism, oxidative stress, and glucose-fatty acid cycle modifications [9] . Consequently, current and past research failures might also be attributed to the fact that traditional research efforts and strategies have not been taking this complexity into account. Indeed, over the last decade, AD molecular mechanisms and drug efficacies have been studied extensively in animal models-primarily in murine models, but also in nonhuman primates, rats, dogs, and other species-all in an effort to assess in animals the contributions of specific genes and proteins to the onset of AD, commonly without accounting for the multifactorial nature of the disease. These animal models consistently fail to accurately recapitulate human AD causes, complex molecular and cellular dynamics, clinical manifestations, and drug responses. This is primarily due to anatomical, biochemical, and physiological as well as genetic and epigenetic interspecies differences between animals and humans [10] . In this review, we propose a novel human-based integrated framework, accounting for multiple levels of biological complexity, which can be used to improve characterization of human AD and develop effective treatments and preventive strategies for human patients.
AD AND INADEQUACY OF TRADITIONAL AD MODELS
The two types of AD are familial AD (∼5% of all AD cases), often occurring before age 60, and lateonset AD ( 95% of all AD cases), occurring in people over the age of 65. Familial AD is generally characterized by the presence of mutations found in genes encoding the ␥-secretase complex components, such as presenilin-1 and −2, or in the amyloid-␤ (A4) protein precursor (A␤PP) [11] . Duplication of the A␤PP gene has also been linked to autosomal dominant familial AD [12] . Late-onset AD is generally defined as 'sporadic', given the lack of specific genetic factors directly associated with the disease. Genome-wide association studies (GWAS) have shown that AD is also associated with variations of several gene loci, such as the apolipoprotein E 4 allele (APOE 4) [13] [14] [15] [16] [17] . Accumulation of amyloid-␤ (A␤) plaques and neurofibrillary tangles, composed of accumulated microtubule-associated total, and phosphorylated tau (t-tau and p-tau) protein, are the two physiological hallmarks of human AD, though it is unclear what role, if any, they play in the disease [18] (Supplementary  Table 1) .
Over the last decade, AD research has focused on the development of animal models to mimic at least some features of human AD described above. However, while certain murine models have been able to exhibit some of the genetic traits found in early-onset familial AD [19] [20] [21] , their suitability to study late-onset AD is questionable [22] , as confirmed by the dramatically high number of failed clinical trials [10, 23] . Without an understanding of the genetics of AD as it occurs in humans, the genetic contribution to disease pathogenesis is virtually impossible to model in mice [24] . In addition to the use of animals, overly simplistic cellular models of AD, often utilizing cancer cell lines or nonhuman cells cultured under nonhomeostatic and nonphysiologic in vitro culture conditions [25] have been commonly applied, further hampering research and drug discovery in AD [10] . Altogether, this highlights the need to rethink current research strategies and improve both sensitivity and specificity of research methods that will mitigate this wide translational gap.
RETHINKING AD RESEARCH FOCUSING ON HUMAN-RELEVANT DATA ACQUISITION
Human-based cellular and tissue models, combined with epidemiological data and high-throughput readouts, can serve as the basis for a paradigm shift in AD research, facilitating human-relevant data acquisition. These tools and novel assays will allow researchers to better elucidate AD pathogenesis in a human-based setting and to design more effective treatments and preventive strategies. To integrate the vast amount of data deriving from comprehensive 'omics' studies, systems biology methods are of fundamental importance. This approach will allow researchers to describe molecular mechanisms underlying AD pathogenesis. In particular, several environmental and lifestyle risk factors, such as specific food nutrients and environmental toxicants, are known to play a pivotal role in the onset of pathologic changes underlying AD, which often appear many years before the symptomatic stages [26] . By using human-based models and novel computational methods, it is now possible to unravel the epigenetic and molecular mechanisms underlying AD pathogenesis (Fig. 1, Table 1 ). 
The population and individual levels: Epidemiological studies and novel 'omics' readouts
Epidemiological studies have been important in identifying AD-related risk factors. The primary risk factors for AD include advancing age [27] [28] [29] , nutritional patterns characterized by low intake of plant-derived foods [30] , together with metabolic syndrome-related dysfunctions (e.g., cardiovascular disease and diabetes) [8, 31] , low socioeconomic status and a low level of educational attainment [32] [33] [34] , low level of daily physical activity [35, 36] , and low cognitive training [37] . Additionally, sleep disorders [38] [39] [40] , known to positively correlate to early A␤ deposition [41, 42] , exposure to air pollution [43] , smoking [44] , and the intake of metals (e.g. aluminum [45] , dietary copper [46] , and manganese [47] ) have been described as possible risk factors. Knowledge of these risk factors may enable the discovery of early biomarkers of AD and the development of intervention strategies to ameliorate or prevent early symptoms of AD.
In particular, analysis of both AD patient-derived plasma and cerebrospinal fluid (CSF) has been proven essential to identify possible early biomarkers of AD ( Table 2 ). The presence of chronic neuroinflammation, caused by the progressive senescence of the immune system and by a sustained secretion of adipose tissue cytokines, seems to play a major role in cardiovascular disease and neurodegeneration [48] , possibly contributing to AD [49, 50] . The presence of high levels of both plasma and brain homocysteine (HCys) is correlated to AD and neurodegenerative disorders. Elevated HCys in brain microvessels may be implicated in the disruption of the blood-brain barrier [51] and induction of excitotoxicity in cells expressing glutamate receptors of the N-methyl-D-aspartate class [52] . Other biomarkers considered relevant to AD are: low levels of plasma uric acid [53, 54] , high levels of serum 3,4-dihydroxybutanoic acid (C 4 H 8 O 4 ), docosapentaenoic acid (C22:5) [55] , and hexacosanoic acid (C26:0) [56] , the presence of insulin resistance and high insulin-like growth factor expression [57] [58] [59] , impaired glycemic levels [60] , mitochondrial damage and increased mitochondrial O-linked N-acetylglucosamine transferase activity [61] , the presence of a dyslipidemic profile [31, [62] [63] [64] [65] [66] , deregulation of plasma orexin [67] [68] [69] [70] , and high levels of the secreted heparin-binding glycoprotein YKL-40 [71, 72] (Table 2) . Additionally, the CSF milieu is altered in subjects presenting AD. Analysis of the CSF revealed the deregulation of several biomarkers currently hypothesized to play a key role for AD early diagnosis, such as the A␤ 1-42 , t-tau, and ptau 181 [73] , and in particular the levels of p-tau 181 /t-tau and p-tau 181 /A␤ 1-42 ratios, considered good indicators of dementia severity and contributing to discrimination between mild or moderate-to-severe AD cases [74] ( Table 2) .
The novel concept of the 'exposome', accounting for the totality of environmental exposures from gestation onward, is currently considered complementary to the genome in the study of disease etiology [75, 76] . In particular, among the possible triggers of the neurodegenerative process and in particular of AD, nutrients have the potential to be either prevention-or riskrelated factors. The study of their effects at the gene expression level, by means of nutrigenomic analyses, is a field of broad scientific interest [77, 78] . Despite some conflicting evidences, plant-based, plant-rich diets and plant-derived bioactive nutrients appear to inhibit neuroinflammation and neurodegeneration molecular and cellular processes [79] and seem to be particularly beneficial in the management of early stages of cognitive impairment [80] [81] [82] [83] [84] . Some nutrigenetic studies have highlighted correlations between specific nutrient intakes and single-nucleotide polymorphisms. In this regard, it has been reported that subjects presenting the TT homozygous methylene tetrahydrofolate reductase allelic variant showed the lowest serum folate level, the highest serum HCys level and the lowest Mini-Mental State Examination (MMSE) score, as compared to all other genotypes [85] . Further studies aiming to identify the genetic susceptibility to AD and the interaction between specific genetic variations and nutrient intake might be invaluable in designing patient-tailored therapies and preventive approaches based on patient genetic makeups. Novel and more powerful in vivo imaging readouts, such as ultra-high-field magnetic resonance imaging (MRI) and positron emission tomography, are currently available to diagnose AD [86, 87] and assess the effects of specific nutritional interventions [88] [89] [90] . Additionally, novel human connectomics (the production and study of connectomes) provides a three-dimensional reconstruction of neuronal networks within the human brain. In particular, diffusion magnetic resonance tractography, by combining MRI and computer-based imaging analysis, allows studying human brain anatomy through 2D and 3D images [91] , and registering variations of brain cortical surfaces in AD patients [92, 93] . Additionally, electron microscopy images have been suitable to generate 3D neuron reconstruction in publicly available electron microscopy datasets [94] . Neuropsychological/cognitive tests (e.g., MMSE and the Hopkins Verbal Learning Test [95] ) can be also used to assess multiple correlations among A␤ plaque distribution, specific AD-related biomarkers in CSF and plasma, and cognitive performance (Fig. 1, Table 1 ).
The organ/tissue and cellular levels: Novel human stem cell models and cell function readouts
In recent years, novel cellular models cultured under conditions more closely reflecting the human physiological cellular microenvironment and accounting for patient heterogeneity have been developed. AD patient-derived primary cells, such as neurons, might represent an ideal cellular source to study AD pathogenic features. However, these cells are generally available only postmortem and are difficult to keep in culture for extended periods of time [96] . To overcome these limitations, human induced pluripotent stem cells (hiPSCs) have been recently applied [97, 98] . hiPSCs can be generated by reprogramming adult somatic cells (e.g., skin fibroblasts) into pluripotent stem cells and further differentiating them in vitro to obtain AD-relevant tissues [10] . hiPSCs have been generated from patients affected with either familial or late-onset AD and have been differentiated into electrophysiologically active neurons, recapitulating common features of AD, such as high level of A␤ , active glycogen synthase kinase 3␤, and p-tau [99] , A␤ accumulation in neuronal cells and astrocytes, and endoplasmic reticulum oxidative stress [100] . Additionally, these differentiated neurons might be useful to identify the specific roles of cellular subtypes in the pathogenesis of AD, to obtain insights into patientspecific drug responses, for prospective diagnostics [101] , and to assess the susceptibility of specific ADrelated genes [102] . More recently, reprogramming of AD patient-derived non-neuronal somatic cells into neuronal mature cells (iNCs) [98, 103] , AD patientderived olfactory mucosa stem cells [96] , genetically modified human neural stem cells (NSCs) [19] , and three-dimensional culture systems [104] have been applied. Additionally, microglial cells, known to get activated in AD [105] , have been derived from elderly patients to define the role of active microglia in the inflammatory process characterizing AD [106] , and can be applied in co-culture systems to complement hiPSC, iNC, and NSC cultures. Moreover, novel brain-on-a-chip systems are currently under development, ideally leading to the design of novel drugs in human-based systems [107, 108] . Despite their current limitations, such as the lack of standardized criteria to build such systems [109] and their poor suitability for long term treatments [110] , in general, these models might better represent the heterogeneity of the patient population, might reduce experimental timeframes and costs, might more accurately identify human AD characteristics, might be better tools for drug development, and might be applicable for use on high-throughput platforms [111] (Fig. 1, Table 1) .
A wide range of high-throughput readouts are currently available to assess etiopathological aspects of AD at tissue and cellular levels. Microelectrode array (MEA) devices have been developed in recent years, as substitutes of the more challenging and timeconsuming patch clamp analyses [112] . Optogenetic techniques, used to monitor the activities of individual neurons in living tissue, together with MEA assays, antibody immunofluorescence (IF) and high content screening (HCS), could enable rapid and reproducible screening of drugs in vitro [96, 113] (Fig. 1, Table 1 ).
The signaling pathway/protein and epigenetic/genetic levels: High-throughput readouts
Several high-throughput technologies are currently available to unravel the molecular mechanisms underlying AD pathogenesis. Protein-related readouts (e.g., proteomics, antibody IF-HCS, metabolomics) will provide knowledge on the signaling pathways and protein interactions that are perturbed in AD at the translational and/or post-translational level (Fig. 1,  Table 1 ). In particular, proteomics and phosphoproteomics have been useful to uncover signaling pathways involved in APOE 4-related late-onset AD [114] . The use of capillary electrophoresis-mass spectrometry can help identify abnormal phosphorylation patterns of proteins implicated in cell metabolism, signal transduction, cytoskeleton integration, and synaptic function [115] . Also, analysis of in vivo metabolites of neuronal and glial cells, representative of energy metabolism, level of inflammation and neurotransmitter release, can be performed by using proton magnetic resonance spectroscopy [116] . Finally, genomics, epigenetics and gene expression analyses (e.g., GWAS, gene expression profiling, nutrigenomics, and nutrigenetics), will serve to identify perturbed gene expression particularly in lateonset AD [117, 118] . Late-onset AD patients often present abnormal patterns of histone acetylation and methylation and deregulated noncoding microRNA, which may play a role in AD pathophysiology [118] .
Computational models, data extrapolation, and functional studies to validate epidemiological observations
Novel computational models that are currently applied in toxicology, such as in vitro-in vivo extrapolation, physiologically based pharmacokinetic and pharmacodynamics modeling, suitable to define kinetics and dynamics of compound exposure and to predict chemical long term effects [119] , might be applied to predict the absorption, distribution, metabolism, and excretion of chemicals, such as chlorpyrifos [120] and manganese [121] , both implicated in A␤ deposition [47, 122] , and also to assess the efficacy of compounds for AD treatment, such as ␤-secretase inhibitors [123] , the bioactive phytocompound curcumin [124] , and APOE 4 inhibitors [125] .
Extrapolation of data obtained from the above described high-throughput readouts and computational simulations might be useful to define early biomarkers of AD, confirm meta-analysis of epidemiological observations, and predict therapeutic efficacy (Fig. 1) . In particular, functional studies might be useful to confirm specific roles of identified perturbed pathways/genes at the onset of AD [126, 127] . In this regard, reporter human cell cultures of an identified perturbed signaling pathway might be generated, in an effort to investigate at high-throughput scale possible perturbation of the identified pathway when exposed to known and unknown compounds, in relation to AD pathogenesis. The ultimate goals would be the definition of novel therapeutic compounds and the implementation of intervention strategies aimed at preventing and/or reducing the early symptoms of AD. Additional in vitro functional studies aimed at defining the role of specific genes in the onset of AD would include gain-or loss-of-function approaches and also RNA interference-induced gene silencing using novel human cellular models of AD [128, 129] .
DISCUSSION
Following decades of extensive research, it is now clear that traditional animal and cell culture models of AD are not reliable for studying complex pathophysiological aspects of the disease or for designing effective drugs. This deep gap in translational research highlights the need for a paradigm shift in AD research, from animal in vivo models and suboptimal in vitro cell lines, toward a more reliable and reproducible human conceptual framework. Here we described an integrated human-based framework suitable for investigating cellular and molecular mechanisms underlying AD pathology, pharmacotherapeutics, and preventive strategies for human patients. In recent years, the shift toward a new human-based paradigm has been advocated extensively in toxicology and regulatory testing [130] , but also in other research fields, including AD [10, [131] [132] [133] [134] . The envisioned human-based framework will not only increase human relevance and translatability, but also contribute to the reduction and/or replacement of animals traditionally used in AD research. In this day and age where there is growing concern for the ethical justification of the use of animals in research [135] , it is important to consider not only the scientific dimensions, but also the ethical cost of the use of sentient beings in AD research.
Several human stem cell models of AD have been developed, spanning from patient-derived neurons and reprogrammed cells to three-dimensional genetically modified NSCs and the more complex brain-on-a-chip. Human stem cell-based tools and high-throughput readouts, supported by epidemiology studies, represent the basis of a paradigm shift in AD research that will increase knowledge of the molecular mechanisms that are perturbed at the onset of the disease, helping define novel biomarkers for early detection, and establishing preventive and treatment strategies.
It should be noted that in the envisioned strategic framework, the use of patient-derived cellular models such as iPSCs, and the application of omics readouts-while addressing human relevance-would still constitute the lower level/scale of 'wet lab' research. Therefore, large computational approaches together with large-scale epidemiological data sets represent the essential tools required to account for higher level/scale and to establish systemic correlations among signaling pathways, epigenomic and genomic perturbations, patients heterogeneity, and lifestyle components. In this regard, a map of signaling pathways and networks that are deregulated in AD is provided by 'AlzPathway', which may help in identifying candidate genes as predictors of AD risk, in combination with other 'omics' data [136] .
Importantly, the implementation of epidemiological, prevention, and intervention clinical studies required to unravel the role of risk factors currently associated with AD, will require increasing the level of current research funding (currently only 7%-9% of the total $30 billion NIH discretionary budget [137] ).
Redefining the strategy by which current and future NIH research budget is allocated is of particular relevance, especially considering the major role played by lifestyle factors, such as nutrition, physical activity, and level of cognitive training in the determination of AD risk [27] [28] [29] [30] [35] [36] [37] as well as the proven efficacy of intervention strategies aimed at preventing dementiarelated symptoms [88] [89] [90] .
In conclusion, combining data derived from a wide range of studies, also accounting for neuropsychological/cognitivity tests, neuroimaging, the analysis of patient-derived CSF-and plasma-related biomarkers, together with computational models and high-throughput readouts applied to patient-derived cell-based models to assess signaling pathways, posttranslational, translational, and transcriptional events, represent an invaluable and more reliable strategy to better understand AD pathology, predict long-term sequelae, and develop successful treatments [10, 138] . The envisioned framework will help redefine human AD pathology and etiology according to a more holistic perspective, taking into account the numerous human-related risk factors implicated in the onset and consolidation of AD [8, 9] . Modern research must take these multifactorial aspects into account. Indeed, current and past research failures may in fact be due to (i) a failure to recognize that AD lies on the spectrum of dementia and may be more accurately considered as part of a constellation of diseases, and/or (ii) more radically, AD may be inexorably linked to aging, making it a more intractable problem with more profound implications than generally acknowledged.
The feasibility of the envisioned human-based strategy necessarily requires the combined application of several methods and readouts and, consequentially, of multiple areas of expertise and laboratory facilities. The establishment of a collaborative scenario is clearly mandatory to determine what occurs throughout the course of AD.
CONCLUSION
Human stem-cell in vitro models, high-throughput ('omics') readouts, computational models, together with data obtained from meta-analysis of epidemiological and interventional studies, are among the ideal tools to elucidate etiopathological aspects of AD in a human-based setting and to predict environmentelicited biological perturbations occurring in AD, accounting for multiple levels of complexity, from population/individual level down to gene level.
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